474,249 Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by William Blair Investment Management LLC

William Blair Investment Management LLC reduced its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Free Report) by 7.2% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,118,972 shares of the company’s stock after selling 474,249 shares during the quarter. Teva Pharmaceutical Industries makes up approximately 0.8% of William Blair Investment Management LLC’s holdings, making the stock its 22nd biggest position. William Blair Investment Management LLC’s holdings in Teva Pharmaceutical Industries were worth $242,311,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Root Financial Partners LLC acquired a new position in Teva Pharmaceutical Industries during the third quarter worth $33,000. Cornerstone Planning Group LLC increased its stake in Teva Pharmaceutical Industries by 547.1% in the 1st quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock valued at $27,000 after buying an additional 755 shares during the last quarter. Western Wealth Management LLC acquired a new stake in Teva Pharmaceutical Industries in the 1st quarter valued at $43,000. Sunbelt Securities Inc. acquired a new stake in Teva Pharmaceutical Industries in the 1st quarter valued at $45,000. Finally, CX Institutional bought a new stake in Teva Pharmaceutical Industries during the 2nd quarter worth about $54,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA opened at $44.52 on Monday. The company has a market cap of $51.88 billion, a price-to-earnings ratio of 103.53, a PEG ratio of 3.85 and a beta of 0.97. Teva Pharmaceutical Industries Ltd. has a 1-year low of $24.01 and a 1-year high of $44.57. The company’s fifty day simple moving average is $40.16 and its 200 day simple moving average is $35.07. The company has a current ratio of 0.95, a quick ratio of 0.74 and a debt-to-equity ratio of 1.59.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.14. The firm had revenue of $4.39 billion for the quarter, compared to analyst estimates of $4.23 billion. Teva Pharmaceutical Industries had a net margin of 2.94% and a return on equity of 33.20%. The company’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.78 earnings per share. On average, research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 1.98 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on TEVA shares. Leerink Partners increased their price objective on shares of Teva Pharmaceutical Industries from $45.00 to $52.00 and gave the stock an “outperform” rating in a research note on Thursday, November 5th. Oppenheimer lifted their target price on Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the company an “outperform” rating in a research report on Friday, October 9th. HC Wainwright initiated coverage on Teva Pharmaceutical Industries in a research report on Monday, November 2nd. They issued a “buy” rating and a $52.00 target price on the stock. TD Cowen upped their target price on Teva Pharmaceutical Industries from $55.00 to $57.00 and gave the stock a “buy” rating in a report on Wednesday, November 4th. Finally, Zacks Research cut Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 20th. Thirteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Teva Pharmaceutical Industries currently has a consensus rating of “Moderate Buy” and an average target price of $48.15.

Check Out Our Latest Stock Report on Teva Pharmaceutical Industries

Insider Activity at Teva Pharmaceutical Industries

In related news, insider Brian Savage sold 7,342 shares of the firm’s stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $38.85, for a total value of $285,236.70. Following the completion of the sale, the insider directly owned 8,500 shares in the company, valued at approximately $330,225. This trade represents a 46.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Mark Sabag sold 46,000 shares of the firm’s stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $41.93, for a total transaction of $1,928,780.00. Following the completion of the sale, the insider owned 80,760 shares of the company’s stock, valued at $3,386,266.80. This trade represents a 36.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 715,945 shares of company stock worth $29,061,351 over the last ninety days. Company insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries Profile

(Free Report)

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.

Recommended Stories

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Free Report).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.